GUFIC BIOSCIENCES LTD. - 509079 - Statement Of Related Party Transactions For Half Year Ended March 31, 2020
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of disclosure pertaining to Related Party Transactions of the Company for the half year ended March 31, 2020. GUFIC BIOSCIENCES LTD. - 509079 - Announcement Under Regulation 30 Of SEBI(Listing Obligation & Disclosure Requirements) Regulations, 2015
This is to inform you that a declaration have been received by the Company from Mrs. Vipula J. Choksi, relative (wife) of Mr. Jayesh P. Choksi, Promoter, Chairman & Managing Director and relative (mother) of Mr. Pranav J. Choksi, Promoter, Chief Executive Officer & Whole Time Director of the Company, holding 28,85,273 number of equity shares aggregating to 3.71% of Paid up share Capital of the Company, that she have neither voted in the past nor will she ever vote on any resolutions proposed by the Company for approval of the shareholders where her husband and/or her son are or may be interested, till the time she remains the shareholder of the Company. The said declaration is enclosed herewith, for your records. GUFIC BIOSCIENCES LTD. - 509079 - Outcome Of Board Meeting
The Board of Directors of the Company at its Meeting held on Tuesday, August 18, 2020 has considered and accepted the resignation tendered by M/s. SHR & CO., (FRN : 120491W) Chartered Accountants, Mumbai as Statutory Auditor of the Company effective from the date on which the financial results for the quarter ended June 30, 2020 are approved by the Board of Directors. The Audit Committee has given their views on the reason for resignation of the Statutory Auditor which the Board took note of, and the same is enclosed herewith. You are requested to take the same on record. GUFIC BIOSCIENCES LTD. - 509079 - Board Meeting Intimation for Notice For Board Meeting Scheduled To Be Held On Tuesday, August 18, 2020
GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/08/2020 ,inter alia, to consider and approve 1.To take note of the resignation of M/s. SHR & Co., Chartered Accountant, as Statutory Auditor of the Company 2.To take note of the views of the Audit Committee over concerns, if any, raised by the Auditor with respect to the resignation, pursuant to SEBI Circular no. CIR/CFD/CMD1/114/2019 dated October 18, 2019 GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith copy of the advertisement published in Newspaper viz. Business Standard and Navshakti on Saturday, August 15, 2020 in respect of notice of Meeting of Equity Shareholders of Gufic Biosciences Limited to be convened on Tuesday, September 15, 2020 at 12:30 P.M. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') pursuant to the order of Hon'ble National Company Law Tribunal , Mumbai bench dated July 14, 2020. GUFIC BIOSCIENCES LTD. - 509079 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Addendum to the Annual Secretarial Compliance Report for the Year ended 31st March, 2020. GUFIC BIOSCIENCES LTD. - 509079 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Addendum to the Annual Secretarial Compliance Report for the Year ended 31st March, 2020. GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
Pursuant to Regulation 30 of SEBI(Listing Obligation & Disclosure REquirements) Regulations, 2015, we wish to inform you that M/s. SHR & Co.,Chartered Accountants (FRN : 120491W), vide its letter dated August 13, 2020, have tendered their resignation from the position of Statutory Auditor of the Company. GUFIC BIOSCIENCES LTD. - 509079 - Shareholder Meeting / Postal Ballot-Court Convened Meeting On September 15, 2020
Pursuant to Regulation 30 read with Schedule III of SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform that in accordance with the order dated July 14, 2020 passed by the National Company Law Tribunal, Mumbai bench under sub-section (1) of Section 230 of the Companies Act, 2013, the Meeting of the Equity Shareholders of the Company is scheduled to be held on Tuesday, September 15, 2020 at 12.30 p.m. through video conferencing or other audio visual means ('VC/ OAVM'), following the operating procedures (with requisite modifications as may be required) for the purpose of considering, and if thought fit, approving with or without modification(s), the proposed Scheme of Amalgamation (Merger by Absorption) of Gufic Lifesciences Private Limited ('Transferor Company') with Gufic Biosciences Limited ('Transferee Company') GUFIC BIOSCIENCES LTD. - 509079 - Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
This is in reference with the Scheme of Amalgamation of Gufic Biosciences Limited ('the Company') with Gufic Lifesciences Private Limited ('GLPL') and their respective shareholders and creditors, for which 'No Observation Letters' have been received by BSE Limited and National Stock Exchange of India Limited vide their letters dated April 15, 2020.As informed in the Management Report submitted on July 31, 2020 along with the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2020, GLPL has entered into a Loan License Agreement with Hetero Labs Limited ('Hetero') to manufacture and supply Remdesivir Lyophilised Powder for injection (100 mg/vial) on loan license basis to Hetero for its sale in various countries including India. Hetero was the first company in India to launch Remdesivir Lyophilised Powder for injection indicated for emergency use in COVID 19 patients.